FeesSafety
Pluang+

AudioEye posts $1M Q3 net income, 58% EBITDA growth, and expects 20% revenue rise in Q4

Company Fundamentals
26 Oct 2026, 23:01 WIB
PRNewsWire
View Source
Bullish
AudioEye posts $1M Q3 net income, 58% EBITDA growth, and expects 20% revenue rise in Q4

AudioEye reported $1 million GAAP net income for Q3 2026, with adjusted EBITDA up 58% year-over-year. The company improved gross margins to 83% and expects continued profitability and approximately 20% sequential annualized revenue growth in Q4. AudioEye also launched two new AI products to enhance digital accessibility and announced a $15 million stock repurchase program. The outlook for full-year 2026 includes revenue between $43.6M-$43.8M and adjusted EBITDA growth of about 50%.

AudioEye's Q3 2026 results provide context for readers interested in recent tech sector performance. As of Oct 27, 2026 02:51 WIB, among 150 priced Technology-sector US stocks tradable on Pluang, 81 rose and 65 fell. Notable movers include EXFY at USD 2.44 with a 1-day change of -5.79% and Pluang order activity showing 84% Sell / 16% Buy, VNET at USD 3.93 with a 1-day change of +5.79% and balanced order activity, and MDB at USD 389.64 with a 1-day change of +5.00% but 100% Sell order activity. The most notable figure is MDB's 100% Sell order activity as of the given time.

More News

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...

Company Fundamentals
Neutral
1 hour ago
Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...

Market News
Bullish
1 hour ago
S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions has been accepted into the SAP PartnerEdge program, marking a key milestone in its growth. This partnership enhances S4A's ability to help organizations maximize their SAP investments, especially in areas like asset management and su...

Market News
Bullish
1 hour ago
SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

Public companies are facing new challenges for the 2027 proxy season due to changes in SEC policies, evolving shareholder activism strategies, and shifts in institutional investor voting. A virtual roundtable on October 28 will gather experts to disc...

Market News
Neutral
3 hours ago
Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo Inc., a leading provider of in-flight broadband connectivity, announced it will report its third quarter 2026 financial results on November 6, 2026, before the market opens. The company will hold a conference call with financial analysts the sam...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App